Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2
Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and fo...
Gespeichert in:
Veröffentlicht in: | Biomedicine & pharmacotherapy 2024-04, Vol.173, p.116378-116378, Article 116378 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 116378 |
---|---|
container_issue | |
container_start_page | 116378 |
container_title | Biomedicine & pharmacotherapy |
container_volume | 173 |
creator | Schmedtje, John F. Ciske, Fred Muzzarelli, Kendall M. Assar, Zahra |
description | Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and found to be nontoxic in the cell lines HMEC-1, A549/hACE2 and VeroE6. CR-0305 induced vasodilation in human coronary arteries ex vivo. Since NO can also have antiviral properties, a study of drug-protein interactions with SARS-CoV-2 was undertaken using in silico modeling. CR-0305 experimentally outperformed the other compounds, including CR-0202, in binding the catalytic site of SARS-CoV-2 papain-like protease (PLpro). PLpro is a primary target for therapeutic inhibition of SARS-CoV-2 as it mediates viral replication and modulates host innate immune responses. CR-0305 is predicted to sit firmly in the PLpro catalytic pocket as confirmed by molecular dynamics simulations, wherein stability of binding to the catalytic site of PLpro induces a conformational change in the BL2 loop to a more closed conformation as observed previously with GRL0617. Surface plasmon resonance was performed with CR-0305 and CR-0202 to characterize binding affinity to purified SARS-CoV-2 PLpro protein. CR-0305 and CR-0202 also inhibited SARS-CoV-2 infection compared to vehicle as measured by virus N protein staining with a specific antibody in A549-ACE2 and VeroE6 cells at 20 µM. CR-0305 is a coronary vasodilator that appears to bind to the catalytic site of the PLpro of SARS-CoV-2 while targeting delivery of antiviral NO to cells infected by SARS-CoV-2, suggesting multiple indications for future development.
•The nitric oxide donor CR-0305, binds the catalytic site of SARS-CoV-2 papain-like protease.•PLpro is a primary target for therapeutic inhibition of SARS-CoV-2.•CR-0305 is a coronary vasodilator that may target delivery of NO to cells infected by SARS-CoV-2. |
doi_str_mv | 10.1016/j.biopha.2024.116378 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2958291432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332224002622</els_id><sourcerecordid>2958291432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-216fb220650cf604aa9c190b40814e60a7445021cd1bebec50c862077040aa213</originalsourceid><addsrcrecordid>eNp9kE1P4zAQhi0EgvLxDxDykUu64484yQUJVbCLhBZp-bhajjMRLmlcbLdi_z2uAnvcky3P83pmHkLOGcwZMPVjOW-dX7-aOQcu54wpUdV7ZMaaEgoFUO2TGVSlKITg_Igcx7gEgFKJ-pAciVo2XIpqRobffosDHV0KzlL_4TqknR99iNQEpNYHP5rwl25N9J0bTNpV0qtJ1AzR09aNHU0-vyBdm7VxYzG4t3wPPqGJSH1PH6__PBYL_1LwU3LQ5xiefZ0n5Pn25mnxq7h_-Hm3uL4vrCirVHCm-pZzUCXYXoE0prGsgVZCzSQqMJWUJXBmO9ZiizZjteJQVSDBGM7ECbmc_s1jvG8wJr1y0eIwmBH9JmrelDVvmBQ8o3JCbfAxBuz1OrhV3lgz0DvPeqknz3rnWU-ec-ziq8OmXWH3L_QtNgNXE4B5z63DoKN1OFrsXECbdOfd_zt8AgCuj1s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2958291432</pqid></control><display><type>article</type><title>Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Schmedtje, John F. ; Ciske, Fred ; Muzzarelli, Kendall M. ; Assar, Zahra</creator><creatorcontrib>Schmedtje, John F. ; Ciske, Fred ; Muzzarelli, Kendall M. ; Assar, Zahra</creatorcontrib><description>Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and found to be nontoxic in the cell lines HMEC-1, A549/hACE2 and VeroE6. CR-0305 induced vasodilation in human coronary arteries ex vivo. Since NO can also have antiviral properties, a study of drug-protein interactions with SARS-CoV-2 was undertaken using in silico modeling. CR-0305 experimentally outperformed the other compounds, including CR-0202, in binding the catalytic site of SARS-CoV-2 papain-like protease (PLpro). PLpro is a primary target for therapeutic inhibition of SARS-CoV-2 as it mediates viral replication and modulates host innate immune responses. CR-0305 is predicted to sit firmly in the PLpro catalytic pocket as confirmed by molecular dynamics simulations, wherein stability of binding to the catalytic site of PLpro induces a conformational change in the BL2 loop to a more closed conformation as observed previously with GRL0617. Surface plasmon resonance was performed with CR-0305 and CR-0202 to characterize binding affinity to purified SARS-CoV-2 PLpro protein. CR-0305 and CR-0202 also inhibited SARS-CoV-2 infection compared to vehicle as measured by virus N protein staining with a specific antibody in A549-ACE2 and VeroE6 cells at 20 µM. CR-0305 is a coronary vasodilator that appears to bind to the catalytic site of the PLpro of SARS-CoV-2 while targeting delivery of antiviral NO to cells infected by SARS-CoV-2, suggesting multiple indications for future development.
•The nitric oxide donor CR-0305, binds the catalytic site of SARS-CoV-2 papain-like protease.•PLpro is a primary target for therapeutic inhibition of SARS-CoV-2.•CR-0305 is a coronary vasodilator that may target delivery of NO to cells infected by SARS-CoV-2.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2024.116378</identifier><identifier>PMID: 38492437</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Antiviral Agents - pharmacology ; Coronary Artery ; COVID-19 ; Humans ; Hypoxia ; Molecular Docking Simulation ; Nitric Oxide ; Nitric Oxide Donors - pharmacology ; Papain ; Papain-Like Protease ; Peptide Hydrolases ; Pharmaceuticals ; Protease Inhibitors ; SARS-CoV-2 ; Vasodilator Agents ; Vasodilators</subject><ispartof>Biomedicine & pharmacotherapy, 2024-04, Vol.173, p.116378-116378, Article 116378</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-216fb220650cf604aa9c190b40814e60a7445021cd1bebec50c862077040aa213</cites><orcidid>0000-0001-6008-6203 ; 0000-0002-1022-8557</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2024.116378$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38492437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmedtje, John F.</creatorcontrib><creatorcontrib>Ciske, Fred</creatorcontrib><creatorcontrib>Muzzarelli, Kendall M.</creatorcontrib><creatorcontrib>Assar, Zahra</creatorcontrib><title>Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and found to be nontoxic in the cell lines HMEC-1, A549/hACE2 and VeroE6. CR-0305 induced vasodilation in human coronary arteries ex vivo. Since NO can also have antiviral properties, a study of drug-protein interactions with SARS-CoV-2 was undertaken using in silico modeling. CR-0305 experimentally outperformed the other compounds, including CR-0202, in binding the catalytic site of SARS-CoV-2 papain-like protease (PLpro). PLpro is a primary target for therapeutic inhibition of SARS-CoV-2 as it mediates viral replication and modulates host innate immune responses. CR-0305 is predicted to sit firmly in the PLpro catalytic pocket as confirmed by molecular dynamics simulations, wherein stability of binding to the catalytic site of PLpro induces a conformational change in the BL2 loop to a more closed conformation as observed previously with GRL0617. Surface plasmon resonance was performed with CR-0305 and CR-0202 to characterize binding affinity to purified SARS-CoV-2 PLpro protein. CR-0305 and CR-0202 also inhibited SARS-CoV-2 infection compared to vehicle as measured by virus N protein staining with a specific antibody in A549-ACE2 and VeroE6 cells at 20 µM. CR-0305 is a coronary vasodilator that appears to bind to the catalytic site of the PLpro of SARS-CoV-2 while targeting delivery of antiviral NO to cells infected by SARS-CoV-2, suggesting multiple indications for future development.
•The nitric oxide donor CR-0305, binds the catalytic site of SARS-CoV-2 papain-like protease.•PLpro is a primary target for therapeutic inhibition of SARS-CoV-2.•CR-0305 is a coronary vasodilator that may target delivery of NO to cells infected by SARS-CoV-2.</description><subject>Antiviral Agents - pharmacology</subject><subject>Coronary Artery</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Molecular Docking Simulation</subject><subject>Nitric Oxide</subject><subject>Nitric Oxide Donors - pharmacology</subject><subject>Papain</subject><subject>Papain-Like Protease</subject><subject>Peptide Hydrolases</subject><subject>Pharmaceuticals</subject><subject>Protease Inhibitors</subject><subject>SARS-CoV-2</subject><subject>Vasodilator Agents</subject><subject>Vasodilators</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1P4zAQhi0EgvLxDxDykUu64484yQUJVbCLhBZp-bhajjMRLmlcbLdi_z2uAnvcky3P83pmHkLOGcwZMPVjOW-dX7-aOQcu54wpUdV7ZMaaEgoFUO2TGVSlKITg_Igcx7gEgFKJ-pAciVo2XIpqRobffosDHV0KzlL_4TqknR99iNQEpNYHP5rwl25N9J0bTNpV0qtJ1AzR09aNHU0-vyBdm7VxYzG4t3wPPqGJSH1PH6__PBYL_1LwU3LQ5xiefZ0n5Pn25mnxq7h_-Hm3uL4vrCirVHCm-pZzUCXYXoE0prGsgVZCzSQqMJWUJXBmO9ZiizZjteJQVSDBGM7ECbmc_s1jvG8wJr1y0eIwmBH9JmrelDVvmBQ8o3JCbfAxBuz1OrhV3lgz0DvPeqknz3rnWU-ec-ziq8OmXWH3L_QtNgNXE4B5z63DoKN1OFrsXECbdOfd_zt8AgCuj1s</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Schmedtje, John F.</creator><creator>Ciske, Fred</creator><creator>Muzzarelli, Kendall M.</creator><creator>Assar, Zahra</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6008-6203</orcidid><orcidid>https://orcid.org/0000-0002-1022-8557</orcidid></search><sort><creationdate>202404</creationdate><title>Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2</title><author>Schmedtje, John F. ; Ciske, Fred ; Muzzarelli, Kendall M. ; Assar, Zahra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-216fb220650cf604aa9c190b40814e60a7445021cd1bebec50c862077040aa213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antiviral Agents - pharmacology</topic><topic>Coronary Artery</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Molecular Docking Simulation</topic><topic>Nitric Oxide</topic><topic>Nitric Oxide Donors - pharmacology</topic><topic>Papain</topic><topic>Papain-Like Protease</topic><topic>Peptide Hydrolases</topic><topic>Pharmaceuticals</topic><topic>Protease Inhibitors</topic><topic>SARS-CoV-2</topic><topic>Vasodilator Agents</topic><topic>Vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmedtje, John F.</creatorcontrib><creatorcontrib>Ciske, Fred</creatorcontrib><creatorcontrib>Muzzarelli, Kendall M.</creatorcontrib><creatorcontrib>Assar, Zahra</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmedtje, John F.</au><au>Ciske, Fred</au><au>Muzzarelli, Kendall M.</au><au>Assar, Zahra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2024-04</date><risdate>2024</risdate><volume>173</volume><spage>116378</spage><epage>116378</epage><pages>116378-116378</pages><artnum>116378</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Several investigational nitric oxide donors were originally created to correct vascular endothelial dysfunction in cardiovascular diseases. These 48 compounds contain an urea-like moiety attached to the well-known NO donors isosorbide 2- and 5-mononitrate. CR-0305 and CR-0202 were synthesized and found to be nontoxic in the cell lines HMEC-1, A549/hACE2 and VeroE6. CR-0305 induced vasodilation in human coronary arteries ex vivo. Since NO can also have antiviral properties, a study of drug-protein interactions with SARS-CoV-2 was undertaken using in silico modeling. CR-0305 experimentally outperformed the other compounds, including CR-0202, in binding the catalytic site of SARS-CoV-2 papain-like protease (PLpro). PLpro is a primary target for therapeutic inhibition of SARS-CoV-2 as it mediates viral replication and modulates host innate immune responses. CR-0305 is predicted to sit firmly in the PLpro catalytic pocket as confirmed by molecular dynamics simulations, wherein stability of binding to the catalytic site of PLpro induces a conformational change in the BL2 loop to a more closed conformation as observed previously with GRL0617. Surface plasmon resonance was performed with CR-0305 and CR-0202 to characterize binding affinity to purified SARS-CoV-2 PLpro protein. CR-0305 and CR-0202 also inhibited SARS-CoV-2 infection compared to vehicle as measured by virus N protein staining with a specific antibody in A549-ACE2 and VeroE6 cells at 20 µM. CR-0305 is a coronary vasodilator that appears to bind to the catalytic site of the PLpro of SARS-CoV-2 while targeting delivery of antiviral NO to cells infected by SARS-CoV-2, suggesting multiple indications for future development.
•The nitric oxide donor CR-0305, binds the catalytic site of SARS-CoV-2 papain-like protease.•PLpro is a primary target for therapeutic inhibition of SARS-CoV-2.•CR-0305 is a coronary vasodilator that may target delivery of NO to cells infected by SARS-CoV-2.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>38492437</pmid><doi>10.1016/j.biopha.2024.116378</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6008-6203</orcidid><orcidid>https://orcid.org/0000-0002-1022-8557</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0753-3322 |
ispartof | Biomedicine & pharmacotherapy, 2024-04, Vol.173, p.116378-116378, Article 116378 |
issn | 0753-3322 1950-6007 |
language | eng |
recordid | cdi_proquest_miscellaneous_2958291432 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals |
subjects | Antiviral Agents - pharmacology Coronary Artery COVID-19 Humans Hypoxia Molecular Docking Simulation Nitric Oxide Nitric Oxide Donors - pharmacology Papain Papain-Like Protease Peptide Hydrolases Pharmaceuticals Protease Inhibitors SARS-CoV-2 Vasodilator Agents Vasodilators |
title | Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A01%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20nitric%20oxide%20donors%20are%20coronary%20vasodilators%20that%20also%20bind%20to%20the%20papain-like%20protease%20of%20SARS-CoV-2&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Schmedtje,%20John%20F.&rft.date=2024-04&rft.volume=173&rft.spage=116378&rft.epage=116378&rft.pages=116378-116378&rft.artnum=116378&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2024.116378&rft_dat=%3Cproquest_cross%3E2958291432%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2958291432&rft_id=info:pmid/38492437&rft_els_id=S0753332224002622&rfr_iscdi=true |